Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: Exploratory analysis from COU-AA-301
Adrenal Cortex Hormones
Antineoplastic Combined Chemotherapy Protocols
Prostatic Neoplasms, Castration-Resistant
Baseline corticosteroids did not adversely affect abiraterone clinical benefit in metastatic castration-resistant prostate cancer. Their use was associated with patients having worse disease characteristics.